24 |
鄂维建, 芦永良, 祁秉民, 等. 血清巨噬细胞极化相关因子与多房棘球蚴病肝纤维化的相关性分析 [J]. 临床肝胆病杂志, 2021,37(12): 2813-2818.
|
25 |
Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients [J].World J Gastroenterol, 2020, 26(34): 5130-5145.
|
26 |
Wang J, Sun X, Wei S, et al. Noninvasive models for the prediction of liver fibrosis in patients with chronic hepatitis B [J]. BMC Gastroenterol, 2024, 24(1): 183.
|
27 |
郝岸华, 杜忠彩, 周林, 等. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨 [J]. 实用肝脏病杂志,2023, 26(5): 630-633.
|
28 |
Ozturk A, Olson MC, Samir AE, et al. Liver fibrosis assessment: MR and US elastography [J]. Abdom Radiol(NY), 2022, 47(9): 3037-3050.
|
29 |
曹建彪, 陈永平, 成军, 等. 瞬时弹性成像技术(TE)临床应用专家共识(2015 年) [J/OL].中国肝脏病杂志(电子版), 2015, 7(2):1218.
|
30 |
Lorée H, Bastard C, Miette V, et al. Vibration-guided transient elastography:a novel Fibroscan® examination with improved guidance for liver stiffness measurement [J]. Ultrasound Med Biol, 2020, 46(9):2193-2206.
|
31 |
武永萍, 魏占芳, 石栓柱, 等. 瞬时弹性超声成像在评价乙型肝炎肝纤维化严重程度中的价值 [J]. 肝脏, 2019, 24(8): 905-907.
|
32 |
尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022 年版) [J].实用肝脏病杂志, 2023, 26(3): 457-478.
|
33 |
王民, 刘婷婷, 王晓明, 等. 评价声辐射力脉冲成像诊断非酒精性脂肪性肝病纤维化的效能 [J]. 临床和实验医学杂志, 2018, 17(2):124-128.
|
34 |
Bui HH, Vo VH, Nguyen CD, et al. Diagnostic performance of acoustic radiation force impulse imaging in evaluating liver fibrosis in patients with chronic hepatitis B infection: A cross-sectional study [J].Indian Radiol Imaging, 2022,32 (3): 287-293.
|
35 |
Zhang X, Huang P, Wang X, et al. Development and validation of a non-invasive model for diagnosing HBV-related liver cirrhosis [J].Clin Chim Acta, 2021, 523: 525-531.
|
36 |
何桥, 原文聪, 樊海宁, 等. 弹性成像联合血清学诊断慢性乙型肝炎肝纤维化的研究现状 [J]. 临床肝胆病杂志, 2021, 37(12): 2914-2918.
|
37 |
车艳玲, 蒋敏, 徐皓煊, 等. 超声剪切波弹性成像在慢性乙型肝炎肝纤维化诊断中的应用 [J]. 中国临床保健杂志, 2022, 25(5): 682-685.
|
38 |
韩磊, 邬超, 张同, 等. 影像技术在肝纤维化诊断应用中的研究进展 [J]. 中国医学装备, 2023, 20(12): 196-200.
|
39 |
Jhaveri KS, Hosseini-Nik H, Sadoughi N,et al. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis [J]. Eur Radiol. 2019, 29(2): 1039-1047.
|
40 |
Fu F, Li X, Chen C, et al. Non-invasive assessment of hepatic fibrosis: comparison of MR elastography to transient elastography and intravoxel incoherent motion diffusion-weighted MRI [J]. Abdom Radiol (NY), 2020, 45(1): 73-82.
|
41 |
Park HS, Choe WH, Han HS, et al. Assessing significant fibrosis using imaging -based elastography in chronic hepatitis B patients:Pilot study[J]. World J Gastroenterol, 2019, 25(25): 3256-3267.
|
42 |
沈萍, 马盛元, 许华宇, 等. MR 弹性成像对慢性乙型肝炎肝纤维化的诊断价值 [J]. 中华放射学杂志, 2019, 53(8): 710-714.
|
43 |
Jiang H, Chen J, Gao R, et al. Liver fibrosis staging with diffusionweighted imaging: a systematic review and meta-analysis [J]. Abdom Radiol(NY), 2017, 42(2): 490-501.
|
1 |
彭颖. 慢性肝病进展的危险因素及预测评估模型 [D]. 重庆: 中国人民解放军陆军军医大学, 2023.
|
2 |
朱红梅, 王勤英. 非酒精性脂肪性肝病肝纤维化的诊断和治疗进展 [J]. 临床肝胆病杂志, 2020, 36(1): 178-181.
|
3 |
Li Y, Yang Y, Li Y, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis [J]. J Int Med Res,2021, 49(11): 03000605211055378.
|
4 |
Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease [J].Metabolism, 2020, 111S: 154259.
|
5 |
Wei YB, Jang CH. Visualization of cholylglycine hydrolase activities through nickel nanoparticle-assisted liquid crystal cells [J]. Sensors and Actuators, 2017, B239(FEB): 1268-1274.
|
6 |
李松鹏, 景红艳. 甘胆酸(CG)在肝炎检测中的应用价值 [J]. 中外医疗, 2018, 37(17): 190-191+198.
|
7 |
Aleknavičiūtė-Valienė G, Banys V. Clinical importance of laboratory biomarkers in liver fibrosis [J]. Biochem Med (Zagreb), 2022, 32(3):030501.
|
8 |
魏莎, 陈晰, 章臻翊, 等. 肝纤维化的早期血清标志物研究进展 [J].实用预防医学, 2024, 31(2): 252-257.
|
9 |
王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展 [J/OL]. 中华临床医师杂志(电子版), 2024, 18(7):677-681.
|
10 |
倪雅惠, 秦东媛, 王琳. 肝硬化患者血清总胆汁酸、高尔基体蛋白73 及糖类抗原19-9 的水平变化及其临床意义 [J]. 中国普通外科杂志, 2024, 33(2): 305-310.
|
11 |
Yao M, Wang L, Leung PSC, et al.The clinical significance of GP73 in immunologically mediated chronic liver diseases:experimental data and literature review [J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
|
12 |
马杨青, 范海纳, 孙鑫, 等. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值 [J]. 临床肝胆病杂志, 2023, 39(8): 1999-2004.
|
13 |
Wang X, He Y, Mackowiak B, et al. MicroRNAs as regulators,biomarkers and therapeutic targets in liver diseases [J]. Gut, 2021,70(4): 784-795.
|
14 |
黄璐, 吴有斌, 倪毅然, 等. miRNAs 在肝纤维化中的作用机制 [J].协和医学杂志, 2023, 14(6): 1251-1257.
|
15 |
Matsumoto Y, Itami S, Kuroda M, et al. MiR-29a assists in preventing the activation of Human stellate cells and promotes recovery from liver fibrosis in mice [J]. Mol Ther, 2016, 24: 1848-1859.
|
16 |
Alarcon CR, Lee H, Goodarzi H, et al. N6-methyl-adenosine marks primary micro-RNAs for processing [J]. Nature, 2015, 519: 482-485.
|
17 |
Tadokoro T, Morishita A, Masaki T. Diagnosis and therapeutic management of liver fibrosis by microRNA [J]. Int J Mol Sci, 2021,22(15): 8139.
|
18 |
Song L,Chen TY, Zhao XJ, et al. Pterostilbene prevents hepatocyte epithelial -mesenchymal transition in fructose-induced liver fibrosis through suppressing miR-34a/Sirt1/p53 and TGF-beta1/smads signalling [J]. Br J Pharmacol, 2019, 176: 1619-1634.
|
19 |
Tian XF, Ji FJ, Zang HL, et al. Activation of the miR-34 a/ SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs [J]. PLoS One,2016, 11: e158657.
|
20 |
Lee CH, Seto WK, Lui DT, et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes [J]. Diabetes Care, 2021, 44(9): 2089-2097.
|
21 |
王伟, 马玉萍, 马海婷, 等. 血清M2BPGi 联合MRI-DWI 预测丙型肝炎患者肝纤维化的临床价值 [J]. 实用医学杂志, 2018, 34(2):293-296+300.
|
22 |
Baudi I, Inoue T, Tanaka Y. Novel biomarkers of hepatitis B and hepatocellular carcinoma: clinical significance of HBcrAg and M2BPGi [J]. Int J Mol Sci, 2020, 21(3): 949.
|
23 |
Ito K, Murotani K, Nakade Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis:a meta-analysis [J]. J Gastroenterol Hepatol, 2017, 32(12): 1922-1930.
|